Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RG3502 in HER2-positive locally advanced/recurrent or metastatic breast cancer
jRCT2080221240Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2010
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in breast cancer, sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080221240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221240.